Effects of atorvastatin on serum lipids, lipoproteins, and hemostasis

American Journal of Hematology

Volumn 78, Issue 1, 2005, Pages 1-6

  Kushiya, Fumihiko ^a   Wada, Hideo ^a   Ooi, Kinue ^a   Sakurai, Yuko ^a   Sakaguchi, Akane ^a   Noda, Maki ^a   Abe, Yasunori ^b   Nakasaki, Takahiro ^c   Tsukada, Tetsuya ^d   Shiku, Hiroshi ^a   Nobori, Tsutomu ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY HOSPITAL   (Japan)

^c Department of Internal Medicine   (Japan)

^d Takeuchi Hospital   (Japan)

Author keywords

Atherogenesis; Atherosclerosis; Atorvastatin; Colestimide; Hypercoagulability; Hyperlipidemia; Lipids; Lipoproteins

Indexed keywords

ATORVASTATIN; CHOLESTEROL; COLESTILAN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ELECTROPHORETIC MOBILITY; FEMALE; HEMOSTASIS; HUMAN; HYPERLIPIDEMIA; ISCHEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL;

ADULT; AGED; ANION EXCHANGE RESINS; ELECTROPHORESIS, AGAR GEL; EPICHLOROHYDRIN; FEMALE; HEMOSTASIS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; IMIDAZOLES; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; PYRROLES; RESINS, SYNTHETIC;

EID: 19944373380     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20191     Document Type: Article

References (30)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
2. Long-Term Intervention with Pravastatin in Ischemic Diseases (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart diseases and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of Pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trail investigators. N Engl J Med 1996;335:1001-1009.
4. Homma Y, Kobayashi T, Yamaguchi H, Ozawa H, Sakane H, Nakamura H. Specific reduction of plasma large, light low-density lipoprotein by a bile acid sequestering resin, cholebine (MCI-196) in type II hyperlipoproteinemia. Atherosclerosis 1997;129:241-248.
5. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kasttelein JJP, Stalenhoef AFH. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomized, double-blind trial. Lancet 2001;357:577-581.
6. Sever P, Dahlöf B, Poulter NR, et al., for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003;361:1149-1158.
7. Schwartz GG, Olsson AG, Ezekowitz MD, et al., for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of Atorvastatin on early recurrent ischemic events in acute coronary syndromes. J Am Med Assoc 2001;285:1711-1718.
8. Superko HR. Beyond LDL cholesterol reduction. Circulation 1996;94:2351-2354.
9. Thomas MJ. Physiological aspects of low-density lipoprotein oxidation. Curr Opin Lipidol 2000;11:297-301.
10. Gravind JS, Hartmann S, Clemmesen J, Jessen KE, Dam H. Role of lipoperoxidase in human pathology. Part 2. The presence of peroxidized lipids in the atherosclerotic aorta. Acta Pathol Microbiol Scand 1952;30:1-6.
11. Harland WA, Gilbert JD, Steele G, Brooks CJW. Lipids of the human atheroma. Part 5. Atherosclerosis 1971;13:239-246.
12. Harland WA, Gilbert JD, Brooks CJW. Lipids of human atheroma VIII. Oxidized derivatives of cholesteryl linoleate. Biochim Biophys Acta 1973;316:378-385.
13. Yla-herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989;84:1086-1095.
14. Palinski W, Rosenfeld ME, Yl-Herttuala S, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989;86:1372-1376.
15. Rokitansky C, More RH, Haust MD. Atherogenesis and plasma constituents. Am J Pathol 1961;38:527-537.
16. Duguid JB. Pathogenesis of atherosclerosis. Lancet 1949;ii:925-927.
17. Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976;295:369-377.
18. Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1986;314:488-500.
19. Mori Y, Wada H, Nagano Y, Deguchi K, Kita T, Shirakawa S. Hypercoagulable state in the Watanabe heritable hyperlipidemic rabbit, an animal model for the progression of atherosclerosis - effect of probucol on coagulation. Thromb Haemost 1989;61:140-143.
20. Wada H, Mori Y, Kaneko T, et al. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol 1993;44:112-116.
21. Aufenager J, Haux P, Katterman R. Improved method for enzymic determination of cholesterol in lipoproteins separated by electrophoresis on thin layer agarose gels. J Clin Biochem 1989;27:807-813.
22. Winkler K, Nauck M, Siekmeier R, Marz W, Wieland H. Determination of triglyceride in lipoproteins separated by agarose gel electrophoresis. J Lipid Res 1995;36:1839-1847.
23. Miller GJ, Miller NE. Plasma high-density lipoprotein concentration and the development of ischaemic heart diseases. Lancet 1975; i:16-19.
24. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. J Am Med Assoc 1986;256:2835-2838.
25. Heinecke JW, Li W, Muller DM, Bohrer A, Turk J. Cholesterol chlorohydrin synthesis by the myeloperoxidase-hydrogen peroxide system: potential markers from lipoproteins oxidatively damaged by phagocytes. Biochemistry 1994;33:10127-10136.
26. Hazen SL, Hsu FF, Duffin K, Heinecke JW. Molecular chlorine generated by the myeloperoxidase-hydrogen peroxide-chloride system of phagocytes converts low-density lipoprotein cholesterol into a family of chlorinated sterols. J Biol Chem 1996;271:23080-23088.
27. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994;94:437-444.
28. O'Driscoll G, Green D, Taylor RR. Sinvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-1131.
29. Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995;92:3172-3177.
30. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230-235.